ヨルダン - 英語 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية السختيان - sukhtian group - fluticasone propionate 250 mcg, formoterol fumarate dihydrate 10 mcg - 250 mcg, 10 mcg

ヨルダン - 英語 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية السختيان - sukhtian group - fluticasone propionate 50 mcg, formoterol fumarate dihydrate 5 mcg - 50 mcg, 5 mcg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - eformoterol fumarate dihydrate; fluticasone propionate -

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

orion corporation - budesonide; formoterol fumarate dihydrate - inhalation powder - 80/4.5 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

ヨルダン - 英語 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - budesonide 160 mcg/dose, formoterol fumarate dihydrate 4.5 mcg/dose - 160 mcg/dose, dihydrate 4.5 mcg/dose

ヨルダン - 英語 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - budesonide 160 mcg/dose, formoterol fumarate dihydrate 4.5 mcg/dose - 160 mcg/dose, dihydrate 4.5 mcg/dose

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - breyna is indicated for the treatment of asthma in patients 6 years of age and older. breyna should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2 -adrenergic agonist (laba). important limitations of use: breyna 160 mcg/4.5 mcg is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema. breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of copd. breyna 160 mcg/4.5 mcg is the only strength indicated for the treatment of copd. important limitations of use: the use of breyna is contraindicated in the following conditions: there are no adequate and well-controlled studies of budesonide and formoterol fumarate dihydrate inhalation aerosol or one of its individual components, formoterol fumarate, in pre

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

astrazeneca ab - budesonide; formoterol fumarate dihydrate - inhalation powder - 100 mcg/6 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

シンガポール - 英語 - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide; formoterol fumarate dihydrate - powder, metered - 160 mcg/dose - budesonide 160 mcg/dose; formoterol fumarate dihydrate 4.5 mcg/dose

シンガポール - 英語 - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide; formoterol fumarate dihydrate - powder, metered - 80 mcg/dose - budesonide 80 mcg/dose; formoterol fumarate dihydrate 4.5 mcg/dose